Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation

Immunological Reviews

Volumn 183, Issue , 2001, Pages 205-213

  Knechtle, Stuart J ^a   Hamawy, Majed M ^a   Hu, Aizhong ^a   Fechner Jr , John H ^a   Cho, Clifford S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; CD 154 ANTIBODY; CYCLOSPORIN A; FN 18 CRM 9; IMMUNOTOXIN; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; OKT 3; PREDNISONE; UNCLASSIFIED DRUG;

DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MONKEY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD3; CD40 LIGAND; HUMANS; IMMUNOTOXINS; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; MODELS, ANIMAL; TRANSPLANTATION TOLERANCE;

EID: 0035672339     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2001.1830116.x     Document Type: Review

References (67)

1. Transplantation - The Johannesburg experience. Current status and prospects for specific tolerance
2. Transplantation tolerance in primates following total lymphoid irradiation and allogeneic bone marrow injection. I. Orthotopic liver allografts
3. Transplantation tolerance in primates following total lymphoid irradiation and allogeneic bone marrow injection. II. Renal allografts
4. Transplantation tolerance in primates after total lymphoid irradiation and allogeneic bone marrow injection. III. Lymphocyte responsiveness and suppressor cell activity
5. Clinical development of Orthoclone OKT3
6. The rejection of renal homografts inhibition in dogs by 6-mercaptopurine
7. A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs
8. Cyclosporin A - A powerful immunosuppressant in dogs with renal allografts
9. Evolutionary stability of transspecies major histocompatibility complex class II DRB lineages in humans and rhesus monkeys
10. Sequence and diversity of rhesus monkey T-cell receptor β chain genes
11. Evolutionary conservation of major histocompatibility complex-DR/peptide/T cell interactions in primates
12. Structure, diversity, and evolution of the T-cell receptor VB gene repertoire in primates
13. A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing
14. Identification of new mamu-DRB alleles using DGGE and direct sequencing
15. Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. II. Effects of adjuvant immunosuppressive drugs
16. Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation
17. Treatment with immunotoxin
18. Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptor-binding moiety in a disulfide conjugate. I. Synthesis of diphtheria toxin fragment A-S-S-human placental lactogen with methyl-5-bromovalerimidate
19. Structure and activity of diphtheria toxin. II. Attack by trypsin at a specific site within the intact toxin molecule
20. Diphtheria toxin: Mode of action and structure
21. Transmembrane transport of diphtheria toxin, related toxins, and colicins
22. How protein toxins enter and kill cells
23. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity
24. The role of the diphtheria toxin receptor in cytosol translocation
25. Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia
26. Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diphtheria toxin and toxin mutants
27. Development of an immunotoxin with in vivo efficacy for murine systems
28. Influence of endogenous Thy1.1 cells upon the efficacy of an anti-Thy1.1 antibody-diphtheria toxin conjugate
29. In vivo T-cell ablation by a holo-immunotoxin directed at human CD3
30. +, and MHC class II positive cells
31. A new reagent for the induction of T-cell depletion, anti-CD3-CRM9
32. Depletion of T lymphocytes with immunotoxin retards the progress of experimental allergic encephalomyelitis in rhesus monkeys
33. FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts
34. Split tolerance induced by immunotoxin in a rhesus kidney allograft model
35. Analysis of primate renal allografts after T-cell depletion with anti-CD3-CRM9
36. Graft survival in a rhesus renal transplant model following immunotoxin-mediated T-cell depletion is enhanced by mycophenolate and steroids
37. + T-lymphocyte regeneration after intensive chemotherapy
38. Peritransplant tolerance induction with anti-CD3-immunotoxin: A matter of proinflammatory cytokine control
39. Peritransplant tolerance induction in macaques: Early events reflecting the unique synergy between immunotoxin and deoxyspergualin
40. Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes
41. Deoxyspergualin inhibits κ light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-κB activation
42. Elucidating the mechanism of action of the immunosuppressant 15-deoxyspergualin
43. Reversal of naturally occurring diabetes in primates by unmodified islet xenografts without chronic immunosuppression
44. Long-term metabolic studies in streptozotin (STZ) induced primate recipients after tolerance induction to allogenic pancreatic islet transplants (PIT)
45. Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-animal model
46. Costimulatory blockade as a therapeutic regimen for prolonging allograft survival and inducing tolerance: An overview of recent research
47. The role of B7-1/B7-2:CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response
48. Costimulatory regulation of T cell function
49. CTLA-4, a negative regulator of T-lymphocyte activation
50. Negative regulation of T cell activation
51. CTLA-4 and T cell activation
52. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model
53. The role of CD40 ligand in costimulation and T-cell activation
54. Regulation of signalling through B-lymphocyte antigen receptors by cell-cell interaction molecules
55. The role of T-cell costimulatory activation pathways in transplant rejection
56. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
57. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in non-human primates
58. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation
59. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment
60. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival
61. CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway
62. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand
63. Prolonged anti-CD40 ligand therapy improves primate cardiac allograft survival
64. CD40:CD154 interactions and allograft rejection
65. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients
66. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients